Introduction {#H1-1-ZOI200150}
============

Previous studies^[@zoi200150r1],[@zoi200150r2],[@zoi200150r3],[@zoi200150r4]^ have raised concerns about selective reporting of outcomes in randomized clinical trials (RCTs). However, few reports have focused on multiplicity, which (along with incomplete reporting) is a major factor contributing to nonreproducibility of published claims.^[@zoi200150r5]^ Multiplicity refers to the "potential inflation of type I error rate as a result of multiple testing, for example because of multiple subgroup comparisons, comparisons across multiple treatment arms, analysis of multiple outcomes, and multiple analyses of the same outcome at different times."^[@zoi200150r6]^

Negative consequences associated with multiplicity could be prevented by complete and accurate reporting of analyses outlined in the registered trial protocols. Multiplicity could also be mitigated by statistical adjustment when multiple analyses are specified a priori. Several statistical methods, such as defining coprimary outcome variables, performing various stepwise procedures,^[@zoi200150r7],[@zoi200150r8],[@zoi200150r9],[@zoi200150r10]^ applying methods for multiple-group comparisons^[@zoi200150r11],[@zoi200150r12]^ and including gatekeeping or hierarchical testing, have been proposed for multiplicity adjustment.^[@zoi200150r13],[@zoi200150r14]^

To our knowledge, no study has reported on the prevalence of multiplicity among cardiovascular RCTs and, when applicable, whether appropriate multiplicity adjustments were implemented. To fill this knowledge gap, we conducted a cross-sectional study of cardiovascular RCTs published in medical journals with high impact factors to assess the reporting quality of statistical analyses, including the frequency with which multiplicity adjustments were reported.

Methods {#H1-2-ZOI200150}
=======

This cross-sectional study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](https://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.^[@zoi200150r15]^ It also followed methods from the American Heart Association on standards for cardiac prevention and treatment studies.^[@zoi200150r16]^

Data Sources and Search Strategy {#H2-1-ZOI200150}
--------------------------------

Three cardiovascular journals (*Circulation*, *European Heart Journal*, and *Journal of the American College of Cardiology*) and 3 general medicine journals (*JAMA*, *The Lancet*, and *The New England Journal of Medicine*) published between August 1, 2015, and July 31, 2018, were searched for general trial characteristics, multiplicity error, and multiplicity correction to assess the pool of recent and contemporary cardiovascular clinical trials. Data were analyzed December 20 to 27, 2018. These journals were chosen based on their high impact factor, broad readership, and reputation of publishing important clinical trials used in the development of guidelines. Supplements and trial protocols of each of the included RCTs were also searched for general trial characteristics, multiplicity error, and multiplicity correction.

Study Selection {#H2-2-ZOI200150}
---------------

Articles were selected if they reported results of cardiovascular RCTs and compared at least 2 treatment groups. Excluded were brief communications, research letters, and animal studies. Data from the selected RCTs were extracted and verified by 2 of us (M.S.K. and Z.N.A.) independently using a structured data instrument and then cross-checked by another of us (T.J.S).

Data Extraction {#H2-3-ZOI200150}
---------------

Data were extracted from both the primary and secondary articles. Primary articles were defined as reports on an empirical research study conducted by the authors analyzing data collected for the first time, while secondary articles were studies derived from data collected and analyzed from primary articles. We analyzed and extracted data only from the analysis of the primary end point of each RCT because multiplicity in a secondary analysis is generally exploratory or hypothesis generating. A multiplicity coding manual was developed to investigate the reporting of primary statistical analyses, multiple analyses, and adjustments for multiplicity issues (eAppendix in the [Supplement](#note-ZOI200150-1-s){ref-type="supplementary-material"}). The multiplicity coding manual was pretested and modified by coding 15 articles initially. Two of us (M.S.K. and Z.N.A.) coded each article separately and discussed any inconsistencies in the data and modified the multiplicity coding manual accordingly. The rest of the articles were then coded according to this multiplicity coding manual. The complete published articles were searched for general trial characteristics, multiplicity error, and multiplicity correction by the coders, along with additional supplementary material (eg, trial protocols and appendixes if they were referred to in the article). The order of the articles was randomized for each coder.

To measure the extent of agreement between the 2 independent coders, the κ statistic was used and calculated according to the methods by Landis and Koch.^[@zoi200150r17]^ The frequency of discrepancies between the coders was computed using the Kappa Calculator (Statistics Solutions),^[@zoi200150r18]^ and the κ statistics were assessed for several outcomes. There was substantial agreement in reproducibility for the presence of multiplicity, with κ = 0.76 (95% CI, 0.51-0.90) in the main text and κ = 0.78 (95% CI, 0.55-0.89) after adjusting for these multiplicity errors. Overall interobserver agreement in extracting data was good, and any discrepancies were resolved after discussion. When consensus could not be reached, another of us (T.J.S.) arbitrated. Finally, a post hoc search was done to assess if the authors of articles stated that their trial was exploratory or hypothesis generating in any section of the article.

General RCT Characteristics {#H2-4-ZOI200150}
---------------------------

The following information was extracted from the RCTs: (1) the number of randomized participants; (2) region of the world where the trial was conducted (North America, Western Europe, multiregional, or rest of the world \[multiregional was defined as any trial that had multiple sites across the world, and rest of the world was defined as any trial having sites in a region that was not located in either North America or Western Europe\]); (3) intervention type (drugs, procedures \[eg, a different approach or method of implementing treatment\], medical devices, surgery, testing or imaging, or other \[eg, diet\]); and (4) funding source. Trial size was extracted (as a proxy for trial phase considering its inconsistent definition) and categorized as small (≤500 participants per group) or large (\>500 participants per group). Trial type (prespecification of a primary end point) was categorized and extracted as either a mortality trial (defined as any trial where the primary outcome was mortality during treatment) or a nonmortality trial.

Outcome Data {#H2-5-ZOI200150}
------------

Data were also extracted for whether the article had risk of multiplicity (ie, contained multiple analyses, a term that encompasses any of the following: multiple treatment groups, multiple outcome variables, and multiple analyses of the same outcome variable) and whether the authors defined the methods used for multiplicity correction. An RCT was considered to have multiple treatment groups if it had more than 2 arms, multiple outcome variables were defined as having more than 1 primary outcome, and multiple analyses were defined as analysis of the same outcome variable in multiple ways. All 3 of these scenarios were weighted equally. We considered multiplicity adjustment sufficient when an article outlined that it attempted to adjust for multiple comparisons.

Statistical Analysis {#H2-6-ZOI200150}
--------------------

Descriptive statistics were used to assess the proportion of RCTs with (1) multiple primary analyses and (2) a multiplicity adjustment for the analysis of the primary end point. Also recorded were the class of multiplicity in the primary analysis (multiple treatment groups, multiple outcome variables, or multiple analyses of the same outcome variable) and frequencies of each of the methods used to adjust for multiplicity in the primary analysis. Multiplicity was examined only for the analysis of the primary end point. It was deemed unnecessary for secondary analyses, which are generally exploratory or hypothesis generating. Outcomes of interest were percentages of primary analyses that performed multiplicity adjustment of primary end points. Two-sided χ^2^ tests were used to examine the association between (1) intervention type, (2) funding source, (3) trial size, and (4) trial type; it was noted whether risk for a familywise error because of multiple comparisons was present and whether the RCT adjusted for multiple comparisons. The method described by Holm^[@zoi200150r8]^ adjusts for multiple comparisons between type of intervention type, funding source, trial size, and trial type. According to this method, the smallest *P* value from all planned comparisons is compared with a significance level of .05 divided by *K*, where *K* represents the number of comparisons to be made. If the null hypothesis is rejected, the next smallest *P* value is compared with a significance level of *P* = .05 divided by *K* minus 1, and so on until the null hypothesis can no longer be rejected. In this scenario, a total of 8 comparisons were made; therefore, the significance level was set to α = .006 (according to .05 ÷ by *K* − 1, where *K* = 8 in this case) in the initial step and to α = .05 in the last step (α being the Holm-corrected significance level). A statistical software package (SPSS, version 23; IBM) was used for all analyses.

Results {#H1-3-ZOI200150}
=======

Literature Search {#H2-7-ZOI200150}
-----------------

The initial search identified 2166 trials, which were transferred to a reference management software program (EndNote, Clarivate Analytics). The titles and abstracts of the identified studies were then screened to exclude irrelevant studies. Full-text studies were subsequently obtained and evaluated for the remaining 1273 reports. After assessing for relevance, 511 articles were included in the final analysis.

Study Characteristics {#H2-8-ZOI200150}
---------------------

Of 511 cardiovascular RCTs included in this analysis, 123 (24.1%) were published in *Journal of the American College of Cardiology*, 112 (21.9%) in *Circulation*, 107 (20.9%) in *European Heart Journal*, 71 (13.9%) in *The New England Journal of Medicine*, 55 (10.8%) in *The Lancet*, and 43 (8.4%) in *JAMA* ([Table 1](#zoi200150t1){ref-type="table"}). Approximately half (248 \[48.5%\]) of the trials were industry funded, and approximately half (243 \[47.6%\]) were large trials. Approximately half (251 \[49.1%\]) of the trials used a drug intervention. A total of 229 trials (44.8%) made use of composite outcomes as their primary outcome variable.

###### Characteristics of 511 Included Randomized Clinical Trials

  Variable                       No. (%)                                                           
  ------------------------------ --------------- ---------------- ---------------- --------------- ----------------
  Total participants, No.        377 591         596 297          687 921          371 819         NA
  Participants per trial, No.    3562            3681             4327             4426            NA
  Journals                                                                                         
  Cardiovascular                 74/342 (21.6)   105/342 (30.7)   105/342 (30.7)   58/342 (17.0)   342/511 (66.9)
  General medicine               32/169 (18.9)   57/169 (33.7)    54/169 (32.0)    26/169 (15.4)   169/511 (33.1)
  Region                                                                                           
  North America                  9 (8.5)         26 (16.0)        31 (19.5)        14 (16.7)       80 (15.7)
  Western Europe                 25 (23.6)       39 (24.1)        34 (21.4)        12 (14.3)       110 (21.5)
  Multiregional                  35 (33.0)       61 (37.7)        57 (35.8)        29 (34.5)       182 (35.6)
  Rest of the world              15 (14.2)       11 (6.8)         11 (6.9)         18 (21.4)       55 (10.8)
  Not mentioned                  22 (20.8)       25 (15.4)        26 (16.4)        11 (13.1)       84 (16.4)
  Intervention type                                                                                
  Drugs                          60 (56.6)       79 (48.8)        73 (45.9)        39 (46.4)       251 (49.1)
  Procedures                     10 (9.4)        23 (14.2)        23 (14.5)        18 (21.4)       74 (14.5)
  Medical devices                7 (6.6)         8 (4.9)          8 (5.0)          5 (6.0)         28 (5.5)
  Surgery                        5 (4.7)         11 (6.8)         7 (4.4)          2 (2.4)         25 (4.9)
  Testing or imaging             0               4 (2.5)          7 (4.4)          4 (4.8)         15 (2.9)
  Other                          24 (22.6)       37 (22.8)        41 (25.8)        16 (19.0)       118 (23.1)
  Funding source                                                                                   
  No source                      0               1 (0.6)          0                1 (1.2)         2 (0.4)
  Government funding             27 (25.5)       52 (32.1)        45 (28.3)        24 (28.6)       148 (29.0)
  University or organization     17 (16.0)       25 (15.4)        30 (18.9)        23 (27.4)       95 (18.6)
  Industry                       58 (54.7)       76 (46.9)        80 (50.3)        34 (40.5)       248 (48.5)
  Not mentioned                  2 (1.9)         6 (3.7)          1 (0.6)          1 (1.2)         10 (2.0)
  Other                          2 (1.9)         2 (1.2)          3 (1.9)          1 (1.2)         8 (1.6)
  Trial size                                                                                       
  ≤500 Participants per group    59 (55.7)       86 (53.1)        80 (50.3)        43 (51.2)       268 (52.4)
  \>500 Participants per group   47 (44.3)       76 (46.9)        79 (49.7)        41 (48.8)       243 (47.6)

Abbreviation: NA, not applicable.

Risk of Multiplicity {#H2-9-ZOI200150}
--------------------

Of 511 cardiovascular RCTs included in this analysis, 300 (58.7%) had some form of multiplicity (282 of 511 \[55.2%\] did not mention whether they did or did not adjust for multiplicity). Of these 300 trials, 81 (27.0%) had multiple treatment groups, 45 (15.0%) identified multiple outcome variables as primary, 170 (56.7%) had multiple analyses of the same outcome variable, 3 (1.0%) had multiple treatment groups and multiple outcome variables, and 1 (0.3%) had multiple treatment groups and multiple analyses ([Table 2](#zoi200150t2){ref-type="table"}).

###### Multiplicity Adjustment

  Variable                                                                                              Frequency, No. (%)
  ----------------------------------------------------------------------------------------------------- --------------------
  Primary analysis contained multiple analyses, of those that identified a primary analysis (n = 511)   300 (58.7)
  Types of multiple analyses included, of those with multiple primary analyses (n = 300)                
  Multiple treatment groups                                                                             81 (27.0)
  Multiple outcome variables                                                                            45 (15.0)
  Multiple analyses of the same outcome variable                                                        170 (56.7)
  Multiple treatment groups and multiple outcome variables                                              3 (1.0)
  Multiple treatment groups and multiple analyses                                                       1 (0.3)
  Adjusted for all multiple comparisons, of those with multiple primary analyses (n = 300)              85 (28.3)

Multiplicity Adjustment {#H2-10-ZOI200150}
-----------------------

Among 300 RCTs, only 85 (28.3%) adjusted for multiplicity for all primary analyses ([Table 2](#zoi200150t2){ref-type="table"}). Of 511 trials, 289 (56.6%) did not mention whether they did or did not attempt to adjust for multiple comparisons. Forty-one trials (48.2%) had multiple analyses of the same outcome variable that adjusted for multiplicity, 22 (25.9%) had multiple treatment groups that adjusted for multiplicity, and 19 (22.4%) had multiple outcome variables that adjusted for multiplicity. The individual multiplicity correction tests are also listed in [Table 3](#zoi200150t3){ref-type="table"}.

###### Methods Used to Adjust for Multiplicity

  Variable                                                                               Articles that adjusted for multiplicity, No. (%)   *P* value                                      
  -------------------------------------------------------------------------------------- -------------------------------------------------- ----------- ----------- ----------- ---------- --------
  ≥2 Coprimary outcome variables with statistically significant treatment associations   1 (1.2)                                            0           1 (5.3)     0           0          \<.001
  Bonferroni adjustment                                                                  15 (17.6)                                          4 (18.2)    2 (10.5)    8 (19.5)    1 (33.3)   \<.001
  Hochberg test                                                                          5 (5.9)                                            2 (9.1)     1 (5.3)     2 (4.9)     0          \<.001
  Dunn test                                                                              3 (3.5)                                            2 (9.1)     0           1 (2.4)     0          \<.001
  Gatekeeping or hierarchical testing                                                    19 (22.4)                                          5 (22.7)    2 (10.5)    11 (26.8)   1 (33.3)   \<.001
  Holm test                                                                              3 (3.5)                                            1 (4.5)     1 (5.3)     1 (2.4)     0          .001
  Adjusted *P* value to account for multiplicity                                         26 (30.6)                                          2 (9.1)     11 (57.9)   13 (31.7)   0          \<.001
  Coprimary outcome variables and gatekeeping                                            3 (3.5)                                            3 (13.6)    0           0           0          \<.001
  Fixed sequence test                                                                    2 (2.4)                                            0           1 (5.3)     0           1 (33.3)   \<.001
  Hommel test                                                                            2 (2.4)                                            0           0           2 (4.9)     0          \<.001
  Dunnett test                                                                           3 (3.5)                                            3 (13.6)    0           0           0          \<.001
  Tukey test                                                                             3 (3.5)                                            0           0           3 (7.3)     0          \<.001

Limitation Specified of Performing Multiplicity Adjustment {#H2-11-ZOI200150}
----------------------------------------------------------

Of 300 trials with multiplicity error risk, 19 (6.3%) were exploratory or hypothesis generating. Twelve of these trials mentioned this exploratory nature in the Discussion section of the article, 5 mentioned it in the Methods section, and 2 mentioned it in more than 1 section of the article. Of the 85 trials that adjusted for multiplicity, 68 (80.0%) mentioned that they adjusted for multiplicity in the main text of the article, and 17 (20.0%) only mentioned it in the supplement or trial protocol.

Determinants of Performing Multiplicity {#H2-12-ZOI200150}
---------------------------------------

Intervention type and funding source had no statistically significant association with the reporting of multiplicity risk adjustment ([Table 4](#zoi200150t4){ref-type="table"}). Trials that assessed mortality vs nonmortality outcomes were more likely to contain a multiplicity risk in their primary analysis (66.3% \[177 of 267\] vs 50.4% \[123 of 244\]; *P* \< .001). Although larger trials had no association with specifying an analysis of the primary end point or containing a multiplicity error risk within their analysis, they were less likely than smaller trials to make any adjustments to correct for multiplicity issues (35.6% \[52 of 146\] vs 21.4% \[33 of 154\]; *P* = .001). All of these results were statistically significant after application of the Holm test.

###### Comparisons of Reporting for Intervention Type, Funding Source, Trial Size, and Trial Type

  Variable                                              Primary analysis has multiple analyses, No./total No. (%)   Adjusted for multiplicity, No./total No. (%)
  ----------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------
  Intervention type                                                                                                 
  Drugs                                                 157/251 (62.5)                                              48/157 (30.6)
  Procedures                                            42/74 (56.8)                                                12/42 (28.6)
  Medical devices                                       17/28 (60.7)                                                4/17 (23.5)
  Surgery                                               17/25 (68.0)                                                2/17 (11.8)
  Testing or imaging                                    8/15 (53.3)                                                 1/8 (12.5)
  Other                                                 59/118 (50.0)                                               18/59 (30.5)
  *P* value[^a^](#zoi200150t4n1){ref-type="table-fn"}   .27                                                         .22
  Funding source                                                                                                    
  None                                                  0/2                                                         0/0
  Government                                            88/148 (59.5)                                               21/88 (23.9)
  University or organization                            54/95 (56.8)                                                16/54 (29.6)
  Industry                                              150/248 (60.5)                                              46/150 (30.7)
  Not mentioned                                         4/10 (40.0)                                                 1/4 (25.0)
  Other                                                 4/8 (50.0)                                                  1/4 (25.0)
  *P* value[^a^](#zoi200150t4n1){ref-type="table-fn"}   .41                                                         .74
  Trial size                                                                                                        
  ≤500 Participants per group                           146/268 (54.5)                                              52/146 (35.6)
  \>500 Participants per group                          154/243 (63.4)                                              33/154 (21.4)
  *P* value[^a^](#zoi200150t4n1){ref-type="table-fn"}   .04                                                         .001
  Trial type                                                                                                        
  Mortality                                             177/267 (66.3)                                              47/177 (26.6)
  Nonmortality                                          123/244 (50.4)                                              38/123 (30.9)
  *P* value[^a^](#zoi200150t4n1){ref-type="table-fn"}   \<.001                                                      .09

*P* values from χ^2^ tests. For 8 comparisons, the ordered *P* values are compared with the Holm-corrected significance levels set at the following values until a comparison fails to reach significance: .0062, .007, .008, .01, .0125, .016, .025, and .05.

Discussion {#H1-4-ZOI200150}
==========

Our report demonstrates that 58.7% of 511 cardiovascular RCTs included in this analysis contained multiple analyses within their methods and that 55.2% of the total RCTs did not report whether they adjusted for multiple comparisons. Trials that assessed mortality were more likely than nonmortality trials to have some form of multiplicity, which is not unexpected because mortality is usually not the sole end point. However, because of the exigent nature of the mortality component and because some researchers consider mortality a safety end point as well, authors might be inclined to claim an association even if the overall end point fails to show effectiveness. These results have important implications for the performance and interpretation of cardiovascular RCTs.

Articles mentioning that they did not adjust for multiplicity often provided some justification, such as stating that their study was exploratory or hypothesis generating. Some justifications were unique to the trial; for example, 1 article mentioned that a chance finding could not be ruled out because of multiple testing and the sample size of the subgroups.^[@zoi200150r19]^ It is possible that results might change before and after multiplicity adjustment; for example, in a trial where *P* = .046 for the primary outcome, the adjusted *P* value may have been different after multiplicity correction.^[@zoi200150r20]^

Among 85 of 511 included articles that adjusted for multiplicity for all primary analyses ([Table 3](#zoi200150t3){ref-type="table"}), half of the trials used a composite outcome as their primary outcome. Composite outcomes allow increased statistical precision and efficiency with fewer participants to detect a statistically significant difference among comparators,^[@zoi200150r21]^ especially in the case of total mortality, which is a rare event requiring more power and an extended follow-up to show a difference between interventions.^[@zoi200150r22]^ Although the use of composite end points is acceptable and in some instances beneficial, it may also increase the risk of introducing a multiplicity error if the observed treatment effect was associated with a softer clinical end point.^[@zoi200150r21],[@zoi200150r23]^ For example, a trial where all-cause mortality, myocardial infarction, and recurrent angina are components of a composite end point, recurrent angina might be considered the softest of the 3 components. The present study did not examine the details of each composite end point of every trial or consider composite end points to be a source of multiplicity; however it suggests the need for future investigators and researchers to apply methods to avoid the possibility of a multiplicity error, as described by Sankoh et al.^[@zoi200150r21]^

Uncertainty in interpreting research results is common and may be attributable to a lack of statistical power or the use of questionable research practices, or it may reflect decisions a researcher makes to conduct a trial.^[@zoi200150r24]^ These uncertainties might explain gaps in the reporting of multiplicity and adjustments made. Conversely, one could also argue that such gaps are less a reflection of multiplicity issues but rather reflect the unavailability of the trial protocol and statistical analysis plan. We suggest that all RCTs in medical journals should describe the trial protocol--specific analytic plan, including the methods used to adjust for multiple comparisons or acknowledgment of the lack of correction for multiplicity. We believe that this inclusion is especially relevant because most clinicians do not have statistical expertise.

Because the criteria used to classify trial phase (ie, phase 1, 2, or 3) were inconsistent among the RCTs in this study, trial size was used as a proxy for trial phase. For drug interventions, smaller trials (≤500 participants per group) may more likely reflect early to middle stages of development, and larger trials (\>500 participants per group) may more likely reflect confirmatory stages.^[@zoi200150r25],[@zoi200150r26]^ Among 161 RCTs, Gewandter et al^[@zoi200150r27]^ found no association between trial size and funding source, with multiplicity adjustment most likely because of the limited power of a study to perform such an analysis. Our analysis included a larger sample of both industry-sponsored RCTs (n = 248) and large RCTs with multiplicity issues (n = 154) ([Table 4](#zoi200150t4){ref-type="table"}). We found that smaller trials were more likely to be adjusted for multiplicity. Funding source had no association with adjusting for multiplicity. This observation suggests that RCTs of drugs in early to middle stages of development may be more likely to adjust for multiplicity.

The appropriateness of testing procedures is guided by information on statistical features of a study design or analytic strategy and differs depending on whether there is a single source of multiplicity or several sources and whether there are multiple treatment groups, multiple outcome variables, or multiple analyses of the same outcome variable. Dmitrienko and D'Agostino^[@zoi200150r23]^ provide some guidance on how to choose the most appropriate test for multiplicity corrections; they state that nonparametric tests, such as the Holm test, can be applied to most multiplicity problems involving a single source of multiplicity. In cases where the association between statistical tests is known, such as in clinical trials with several dose-control comparisons and patient populations, more specific parametric tests, such as the Dunnett test, may be applied. In an effort to better explain types of multiple analyses and multiple outcome variables, detailed examples are listed in eTable 1 in the [Supplement](#note-ZOI200150-1-s){ref-type="supplementary-material"}.

Limitations {#H2-13-ZOI200150}
-----------

This study has several limitations. First, we assessed the reporting quality of the methods used for multiplicity adjustments but not necessarily the quality of statistical practices used. Because the methods may have been prespecified but not stated in the articles,^[@zoi200150r28],[@zoi200150r29]^ this report is subject to reporting bias. Second, studies were recorded as having adjusted for multiplicity in the primary analysis only if the authors adjusted for all instances of multiplicity. However, this approach does not consider the trials that tried to adjust for some but not all sources of multiple comparisons. Also, whether a study had multiple treatment groups, multiple outcome variables, or multiple analyses of the same outcome variable, all had the same weight in terms of adjusting for multiplicity and thus were considered equally. A third limitation is that we only evaluated the primary outcomes. It is important to note that the secondary end point in a sequence may often influence a conclusion. For instance, if a trial finds a statistically significant difference in major adverse cardiovascular events (myocardial infarction, stroke, and admission for heart failure) and the next end point in the sequence is the myocardial infarction rate, which is not statistically significant, it would be incorrect to conclude a nominally statistically significant stroke association. In addition, we were unable to differentiate our analysis by trial type. Although the objective of this study was to evaluate the overall prevalence of multiplicity among cardiovascular RCTs, it must be remembered that phase 3 trials hold the most importance from a public health perspective, and multiplicity is of lesser concern in phase 2 trials.

Conclusions {#H1-5-ZOI200150}
===========

This cross-sectional study found frequent inconsistencies associated with multiplicity in primary analysis reporting among cardiovascular RCTs published in medical journals with a high impact factor. These findings adversely reflect on the robustness of data published in journals that carry global reach and generate evidence that can transform clinical guidelines and practice. Our findings suggest that investigators should be encouraged to adjust for multiplicity when warranted. Practical guidelines for multiplicity adjustment in clinical trials (eg, recommendations by Proschan and Waclawiw^[@zoi200150r30]^) can be consulted. We think that this information should ideally be prespecified in the Methods section of clinical trials before unblinding of the study data (eTable 2 in the [Supplement](#note-ZOI200150-1-s){ref-type="supplementary-material"}). We believe that it should be the collective responsibility of journal editors, peer reviewers, and readers to pay close attention to the Methods and Statistical Analysis sections of articles reporting clinical trial results to ensure that multiplicity issues have been addressed.
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